

- Varnat F, Heggeler BB, Grisel P, Boucard N, Corthesy-Theulaz I, Wahli W, Desvergne B. PPARbeta/delta regulates Paneth cell differentiation via controlling the Hedgehog signaling pathway. *Gastroenterology* 2006;131:538–553.
- Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. *Genes Dev* 2001;15:3059–3087.
- Madison BB, Braunstein K, Kuizon E, Portman K, Qiao XT, Gumucio DL. Epithelial hedgehog signals pattern the intestinal crypt-villus axis. *Development* 2005;132:279–289.
- Lees C, Howie S, Sartor RB, Satsangi J. The hedgehog signalling pathway in the gastrointestinal tract: implications for development, homeostasis, and disease. *Gastroenterology* 2005;129:1696–1710.
- Akiyoshi T, Nakamura M, Koga K, Nakashima H, Yao T, Tsuneyoshi M, Tanaka M, Katano M. Gli1, downregulated in colorectal cancers, inhibits proliferation of colon cancer cells involving Wnt signalling activation. *Gut* 2006;55:991–999.
- Van Den Brink GR, Bleuming SA, Hardwick JC, Schepman BL, Offerhaus GJ, Keller JJ, Nielsen C, Gaffield W, Van Deventer SJ, Roberts DJ, Peppelenbosch MP. Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation. *Nat Genet* 2004;36:277–282.
- Douard R, Moutereau S, Pernet P, Chimingqi M, Allory Y, Manivet P, Conti M, Vaubourdolle M, Cugnenc PH, Loric S. Sonic Hedgehog-dependent proliferation in a series of patients with colorectal cancer. *Surgery* 2006;139:665–670.
- Berman DM, Karhadkar SS, Maitra A, Montes DO, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN, Beachy PA. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. *Nature* 2003;425:846–851.
- Thayer SP, Di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-Del Castillo C, Yajnik V, Antoni B, McMahon M, Warshaw AL, Hebrok M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. *Nature* 2003;425:851–856.
- Kusano KF, Pola R, Murayama T, Curry C, Kawamoto A, Iwakura A, Shintani S, Ii M, Asai J, Tkebuchava T, Thorne T, Takenaka H, Aikawa R, Goukassian D, von Samson P, Hamada H, Yoon YS, Silver M, Eaton E, Ma H, Heyd L, Kearney M, Munger W, Porter JA, Kishore R, Losordo DW. Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. *Nat Med* 2005;11:1197–1204.

doi:10.1053/j.gastro.2006.10.007

Reply. We read with a considerable attention the comments of Lees et al, relative to potential side effects that might occur in the digestive tract while manipulating the Hedgehog (Hh) signaling pathway. Considering these statements, we would like to underline some parallel issues, with likely consequences on cancer therapeutic strategy.

There is first a crucial need of more fundamental studies to reasonably understand the scope of Hh and PPAR β actions in the gastrointestinal (GI) tract, particularly with respect to the risk of cancer development. The correspondence by Lees et al indeed underscores how Hh inhibition is on the one hand proposed to potentially treat a variety of cancer, including colon cancer, while on the other hand potentially promoting colon carcinogenesis.¹ Similar discrepancies are observed concerning the role of PPAR β in the appearance and growth of cancer in the GI tract, with evidence either for protumorigenic^{2–6} or antitumorigenic activity.^{7–9} The PPAR β -mediated down-regulation of Ihh expression, which favors Paneth cell maturation, might also be negatively considered because of the

presence of Paneth cells in familial adenomatous polyposis dysplasia, as well as in the corresponding mouse model.^{10,11} In contrast, it might also be interpreted as one mechanism by which activated PPAR β favors cell differentiation and may protect from GI tumorigenesis.

The second and related issue is that both Hh and PPAR β pathways are active in a broad range of tissues and organs. For each tissue, within the GI tract and outside this organ, they might trigger different responses depending on other interfering pathways that are also active (eg, Wnt, Notch, Akt). For both pathways, the use of systemic agents are presently considered, in cancer, tissue repair and inflammation for Hh, and to treat metabolic disorders for PPAR β .¹² As highlighted in the correspondence by Lees et al, it seems indeed very important to raise a word of caution, proposing a careful and recurrent examination of the GI tract response to these drugs, when given in a non-GI-related pathology. Alternately, manipulating either Hh or PPAR β signaling in the context of tumor, regardless of its localization, should rather be considered in the context of site-specific drug delivery systems, such as with antibody–drug conjugates specifically targeting epitopes present at the cancer cell surface (reviewed Schrama et al¹³).

FRÉDÉRIC VARNAT
BÉATRICE DESVERGNE
Centre Intégréatif de Génomique
Université de Lausanne
Bâtiment Le Génopode
Lausanne, Switzerland

- Lees C, Howie S, Sartor RB, Satsangi J. The hedgehog signalling pathway in the gastrointestinal tract: implications for development, homeostasis, and disease. *Gastroenterology* 2005;129:1696–1710.
- He TC, Chan TA, Vogelstein B, Kinzler KW. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. *Cell* 1999;99:335–345.
- Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer SM, Lippman SM. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. *Proc Natl Acad Sci U S A* 2003;100:9968–9973.
- Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells. *Proc Natl Acad Sci U S A* 2001;98:2598–2603.
- Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. *Nat Med* 2004;10:245–247.
- Wang D, Wang H, Shi Q, Katkuri S, Walhi W, Desvergne B, Das SK, Dey SK, DuBois RN. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. *Cancer Cell* 2004;6:285–295.
- Reed KR, Sansom OJ, Hayes AJ, Gescher AJ, Winton DJ, Peters JM, Clarke AR. PPARdelta status and Apc-mediated tumorigenesis in the mouse intestine. *Oncogene* 2004;23:8992–8996.
- Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. *Cancer Res* 2006;66:4394–4401.
- Harman FS, Nicol CJ, Marin HE, Ward JM, Gonzalez FJ, Peters JM. Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. *Nat Med* 2004;10:481–483.

10. Turner JR, Odze RD. Proliferative characteristics of differentiated cells in familial adenomatous polyposis-associated duodenal adenomas. *Hum Pathol* 1996;27:63–69.
11. Andreu P, Colnot S, Godard C, Gad S, Chafey P, Niwa-Kawakita M, Laurent-Puig P, Kahn A, Robine S, Perret C, Romagnolo B. Crypt-restricted proliferation and commitment to the Paneth cell lineage following *Apc* loss in the mouse intestine. *Development* 2005;132:1443–1451.
12. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. *Trends Pharmacol Sci* 2005;26:244–251.
13. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. *Nat Rev Drug Discov* 2006;5:147–159.

doi:10.1053/j.gastro.2006.10.006

Correction

Mori Y, Cai K, Cheng Y, Wang S, Paun B, Hamilton JP, Jin Z, Sato F, Berki AT, Kan T, Ito T, Mantzur C, Abraham JM, Meltzer SJ. A genome-wide search identifies epigenetic silencing of *Somatostatin*, *Tachykinin-1*, and 5 other genes in colon cancer. *Gastroenterology* 2006;131:797–808.

The third paragraph in the Results section should have read as follows:

In support of our approach, 6 of these genes had been reported to undergo promoter hypermethylation and mRNA down-regulation in human cancers in the literature: RUNX3, HLF/SMARCA3, RAB32, AKAP12, CAV1, and RRAD/REM3. RUNX3, HLF/SMARCA3, and RAB32 were hypermethylated in primary colon cancers, whereas AKAP12, CAV1, and RRAD/REM3 were hypermethylated in non-colonic cancers.^{6,8–10,12,13}

Answer to the Clinical Challenges and Images in GI Question: Image 1 (page 1379): *Yersinia enterocolitica* Mesenteric Adenitis and Terminal Ileitis

The presentation and clinical studies supported a differential diagnosis of malignancy, Crohn's disease, as well as infectious mesenteric adenitis. Histological findings from colonic biopsies revealed severe acute colitis with neutrophils infiltrations, acute ulceration, and necrosis. Stool cultures yielded growth of *Yersinia enterocolitica*. The patient was treated with antibiotics based on sensitivity test. His symptoms resolved promptly with medical therapy alone. Twenty-four days later, follow-up colonoscopy showed complete healing of the ulcer. The patient recovered completely and was discharged without surgery. Two months later, abdominal CT showed a clear regression of enlarged mass. Retrospectively, the CT findings were compatible with mesenteric adenitis.

Infection with *Y enterocolitica* is usually a benign, self-limited disorder characterized by fever, diarrhea, abdominal pain, mesenteric adenitis, erythema nodosum, or other immunologic manifestations. Emergency intestinal resections have been performed in some patients, however, and some have died of fulminant disease. *Yersinia* septicemia can occur during acute infection, particularly infants and those with impaired immune defenses or iron-overload states.^{1,2} *Y enterocolitica* usually invades *via* Peyer's patches, causing microabscesses, and ulceration of the overlying epithelium. The organism commonly involves the terminal ileum and can invade mesenteric nodes.³ Mesenteric adenities, which is the most common clinical manifestation, causes a pseudoappendicular syndrome. However, there have been very few reports of *Yersinia* infection presenting as an abdominal mass.⁴ Although rare, as in our case, it can present with an abdominal mass caused by pathologic enlargement of one or more of the mesenteric lymph nodes in the ileocecal region. *Yersinia* infection should be considered in patients with a right lower abdominal mass.

References

1. Vantrappen G, Ponette E, Geboes K, Bertrand P. *Yersinia* enteritis and enterocolitis: gastroenterological aspects. *Gastroenterology* 1977;72:220–227.
2. Butler T, Dennis DT. *Yersinia* species, including plague. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 6th ed, Vol. 2. Philadelphia: Elsevier, 2005:2691–2700.
3. Crosbie J, Varma J, Mansfield J. *Yersinia enterocolitica* infection in a patient with hemachromatosis masquerading as proximal colon cancer with liver metastases: report of a case. *Dis Colon Rectum* 2005;48:390–392.
4. Sue K, Nishimi T, Yamada T, Kamimura T, Matsuo Y, Tanaka N. A right lower abdominal mass due to *Yersinia* mesenteric lymphadenitis. *Pediatr Radiol* 1994;24:70–71.

For submission instructions, please see the GASTROENTEROLOGY website (<http://www.gastrojournal.org>).